fbpx
March 5, 2021

Public Notification: Rhino SE7EN2 contains hidden drug ingredients

[3-5-2021] The Food and Drug Administration is advising consumers not to purchase or use Rhino SE7EN2, a product promoted and sold for sexual enhancement on various […]
March 5, 2021

Public Notification: Titanium 18K contains hidden drug ingredients

[3-5-2021] The Food and Drug Administration is advising consumers not to purchase or use Titanium 18K, a product promoted and sold for sexual enhancement on various […]
March 5, 2021

Public Notification: Stiff Rox contains hidden drug ingredients

[3-5-2021] The Food and Drug Administration is advising consumers not to purchase or use Stiff Rox, a product promoted and sold for sexual enhancement on various […]
March 5, 2021

Public Notification: 2 Own The Knight Silver 4000 contains hidden drug ingredients

[3-5-2021] The Food and Drug Administration is advising consumers not to purchase or use 2 Own The Knight Silver 4000, a product promoted and sold for […]
March 5, 2021

Coronavirus (COVID-19) Update: March 5, 2021

For Immediate Release: March 05, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 […]
March 5, 2021

Why You Should Not Use Ivermectin to Treat or Prevent COVID-19

Image COVID-19. We’ve been living with it for what sometimes seems like forever. Given the number of deaths that have occurred from the disease, it’s perhaps […]
March 4, 2021

COVID-19 Container Closure System and Component Changes: Glass Vials and Stoppers Guidance for Industry

Docket Number: FDA-2020-D-1136 Issued by: Guidance Issuing Office Center for Biologics Evaluation and Research Center for Drug Evaluation and Research FDA plays a critical role in […]
March 4, 2021

SafaLab, Inc. – 611233 – 02/18/2021

Product: DrugsFood & Beverages WARNING LETTER Date: February 18, 2021 RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19) This is to advise you […]
March 4, 2021

FDA approves lorlatinib for metastatic ALK-positive NSCLC

On March 3, 2021, the Food and Drug Administration granted regular approval to lorlatinib (Lorbrena, Pfizer Inc.) for patients with metastatic non-small cell lung cancer (NSCLC) […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0